Prevymis 240 Mg Iv 240 mg Concentrate for Solution for Infusion
PDF Leaflet Revision Date: 15 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prophylaxis of CMV reactivation in adult HSCT recipients.
Dosage (summary)
480 mg once daily, starting post-HSCT.
Onset of Action / Duration
Onset: 28 days, Duration: 100 days
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; avoid breastfeeding.
Key Drug Interactions
- CYP3A substrates
- Ciclosporin
- Statins
Contraindications
- Hypersensitivity
- Pimozide
- Ergot alkaloids
- St. John's wort
Common side effects
- Nausea
- Diarrhoea
- Vomiting
Counselling Points
- Take as prescribed
- Do not double doses
- Report any severe side effects
Serious warnings
- Monitor CMV DNA
- Risk of drug interactions
Important Disclaimer
The Prevymis 240 Mg Iv 240 mg Concentrate for Solution for Infusion professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
